Across TCGA pan-cancer cohorts, PRAME Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRAME data layer compared with 27 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PRAME Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAME expression acts as an unfavorable survival marker.
SKCM, PRAD, and BRCA are the cancer types where PRAME Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.